Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625802 | 0.89 | NOTUM (0.50) | NOTUMADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL12905282 | 0.81 | NOTUM (0.54) | NOTUMADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL2625804 | 0.78 | ALOX12 (0.50) | NOTUMADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL18329546 | 0.76 | MAOA (0.41) | NOTUMADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL21288160 | 0.76 | MAOA (0.41) | NOTUMADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL23346676 | 0.76 | DRD2 (0.41) | NOTUMADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL23181523 | 0.76 | DRD2 (0.41) | NOTUMADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL2625787 | 0.76 | MAOA (0.41) | NOTUMADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL18329551 | 0.76 | NOTUM (0.53) | NOTUMADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL22193281 | 0.76 | NOTUM (0.53) | NOTUMADRA2AADRA2BADRA2CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2022087624-A1 | COMPOUNDS AS RAS INHIBITORS AND USES THEREOF | BIOARDIS LLC (US) | 2022-04-28 | — | — | WO | disclosed |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | UBE INDUSTRIES, LTD. (JP) | 2021-01-19 | — | — | US | disclosed |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2021-01-07 | — | — | US | disclosed |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 2019-08-22 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7223757-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-29 | — | — | US | disclosed |
| US-7081454-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2006-07-25 | — | — | US | disclosed |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | WITTMAN MARK D | 2006-04-13 | — | — | US | disclosed |
| EP-1545543-A2 | NOVEL TYROSINE KINASES INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| CN-1514833-A | Novel tyrosine kinase inhibitors | ����˹�ж�-����˹˹������˾ | 2004-07-21 | — | — | CN | disclosed |
| WO-2004031401-A2 | NOVEL TYROSINE KINASES INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
| EP-1381598-A1 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002079192-A1 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256531-A1 | SUBSTITUTED DIHYDROPYRROLOPYRAZOLE DERIVATIVE | QDPR, CYP11B2, CYP4F3 | NOTUM 2906/4885ADRA2A 557/4885ADRA2B 286/4885 |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | NOTUM 4477/4885ADRA2A 43/4885ADRA2B 74/4885 |
| US-20210238164-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | NOTUM 4477/4885ADRA2A 43/4885ADRA2B 74/4885 |
| US-10604507-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | NOTUM 4477/4885ADRA2A 43/4885ADRA2B 74/4885 |
| US-10894798-B2 | Substituted dihydropyrrolopyrazole derivative | QDPR, CYP11B2, CYP4F3 | NOTUM 2906/4885ADRA2A 557/4885ADRA2B 286/4885 |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | NOTUM 4477/4885ADRA2A 43/4885ADRA2B 74/4885 |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | NOTUM 3139/4885ADRA2A 4612/4885ADRA2B 4198/4885 |
| US-20210002254-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | NOTUM 4477/4885ADRA2A 43/4885ADRA2B 74/4885 |
| US-10766877-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | NOTUM 4477/4885ADRA2A 43/4885ADRA2B 74/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | NOTUM 4477/4885ADRA2A 43/4885ADRA2B 74/4885 |
| US-20060079518-A1 | Novel tyrosine kinase inhibitors | ABL1, FER, ERBB2 | NOTUM 2904/4885ADRA2A 4702/4885ADRA2B 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.